Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

NCT06620068 | Not Yet Recruiting

• 1 other identifier: FSKY20240924
• Study Type: observational
• Target: 207,473
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Conditions

Placenta Previa

Keywords

Vascular Endothelial Growth Factor (VEGF); Mendelian Randomization; Angiogenesis; Pregnancy Complications; Placental Development

Outcome Measures

Primary Outcomes (1)

• Causal relationship between plasma VEGFA levels and the risk of placenta previa

  This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

  Data analysis and outcome assessment will be completed by December 2024

Secondary Outcomes (3)

• Causal relationship between plasma VEGFB levels and the risk of placenta previa

  Data analysis and outcome assessment will be completed by December 2024

• Causal relationship between plasma VEGFC levels and the risk of placenta previa

  Data analysis and outcome assessment will be completed by December 2024

• Causal relationship between plasma PLGF levels and the risk of placenta previa

  Data analysis and outcome assessment will be completed by December 2024

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.

You may qualify if:

• Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

You may not qualify if:

• Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Sponsors & Collaborators

• Guangzhou Institute of Respiratory Disease: lead
• The Second People's Hospital of Foshan: collaborator
• First People's Hospital of Foshan: collaborator
• Maternal and Child Health Hospital of Foshan: collaborator

Biospecimen

Retention: SAMPLES WITH DNA

The study utilizes genome-wide association study (GWAS) data from publicly available biobanks (e.g., UK Biobank and FinnGen), which include samples with DNA.

MeSH Terms

Conditions

Placenta Previa; Pregnancy Complications

Condition Hierarchy (Ancestors)

Obstetric Labor Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Placenta Diseases

Central Study Contacts

Zhibin Xu

CONTACT

+8615816832640; unignorable_xuzhibin@outlook.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 24, 2024
• First Posted: October 1, 2024
• Study Start: September 25, 2024
• Primary Completion: November 1, 2024
• Study Completion: December 1, 2024
• Last Updated: October 1, 2024

Record last verified: 2024-09